In the wake of the COVID-19 pandemic, markets across healthcare have changed dramatically. In particular, the market for general radiography and fluoroscopy systems has experienced a significant shift, with chest x-ray examinations identified as a key tool to diagnose and track the progression of late-stage COVID-19.
The need for access to x-ray imaging within intensive care departments has skyrocketed, creating unprecedented demand for mobile x-ray systems, which are easy to clean and transport between wards. For example, OEM manufacturer Micro-X published an increase in revenue of 375% in its first quarter of 2020 compared with the same period of 2019. Many other leading vendors have cited substantial increases in orders.
In contrast, sales of fluoroscopy and fixed x-ray radiography rooms have dropped, as budgets are sequestered to focus on pandemic response. Site-access restrictions have prevented or delayed prescheduled installations.
Such market volatility has created many challenges for the x-ray manufacturing segment, and while predicting what's ahead in the coming months and years is very difficult, many are still asking: what happens next?
A sharp return to normalcy
At Signify Research we have taken the view that the x-ray market will experience a sharp V-shaped recovery in most regions, beginning in the second half of 2020. As lockdown measures are lifted and healthcare systems readjust, we expect pent-up demand for fixed radiography and fluoroscopy systems to be quickly realized. Previously scheduled orders for 2020 may push into 2021 as order backlogs will take time to fulfill. As outlined in Figure 1, most markets segments (excluding mobile and analog) should return to prepandemic performance by 2022.
Ana = analogWe have come to this conclusion for the following reasons:
1) The change in demand for imaging procedures is temporary, and volume is likely to surge post-COVID-19.
Changes to market conditions in the first quarter of 2020 were rapid as the COVID-19 pandemic escalated, creating a shock to healthcare systems. In their reaction, healthcare providers entered crisis-mode and channeled resources toward pandemic responses, sequestering budgets for critical care equipment. Previously scheduled orders deemed nonessential to the pandemic response were also delayed, with movement restrictions preventing onsite implementation activity. Elective procedures and normal operations in many clinical departments were also put on hold, leading to imaging volumes for noncritical exams experiencing massive drops.
Initial evidence shows some modalities were affected more than others, as in the figure below:
An April 2020 survey by IMV Medical Information Division showed more than 50% of healthcare provider respondents in Europe expected these volumes to return to normal in two to three months, whereas almost 25% expect this to take more than four months.
As the effect of the virus lessens and restrictions are lifted in the second half of 2020, many radiologists are expecting a "reservoir" of scheduled exams to spike demand and create new challenges for healthcare providers to address. The knock-on effect of high exam volume will be increased wear and tear on existing x-ray systems and a growing focus on efficiency and patient throughput.
For this reason, healthcare providers are unlikely to cancel or postpone the installation of previously scheduled radiography and fluoroscopy system replacements and instead are more likely to bring forward renewals in order to increase efficiency. As logistical channels reopen, we predict a clear upturn, continuing into 2021 and 2022.
2) Order books remain healthy.
Recent financial guidance from healthcare technology vendors have made it very clear a drastic market decline is not expected midterm, with orders merely delayed rather than canceled. This is something echoed across all healthcare markets to some extent from our analysis of recent financial investor calls, with vendors reporting healthy order books.
"In equipment, we believe there will be pent-up demand as the crisis does not change the underlying health care drivers," said Siemens Healthineers CEO Bernd Montag. "When it comes to installations, we have a very healthy order book. And this is just a timing topic when hospitals get back to taking deliveries."
That sentiment was echoed by Abhijit Bhattacharya, chief financial officer of Philips Healthcare.
"It is important to note that we have not seen any cancellation of orders due to the COVID-19 outbreak," Bhattacharya said.
3) Radiography and fluoroscopy will likely be least affected by potential imaging budget cuts, though emerging markets have a more risky outlook.
In addition to this, midterm healthcare budgets are less likely to be slashed as providers benefit from the range of stimulus packages designed to support them in this difficult time. The U.S., China, Japan, and Europe, which together account for most of the market, have all announced multibillions in preparation for this, although it is unclear how effective these will be at this early stage.
General radiography equipment is generally priced much cheaper than CT or MRI modalities. In some regions, asking prices are as low as $35,000 for a fixed system, whereas CT and MRI scanners typically are sold for more than $500,000. In addition to being a lower-cost purchase, general radiography equipment is also still some of the most frequently used in the hospital, with a recent IMV survey estimating a total of 152.8 million exams performed in the U.S. on general x-ray equipment in 2018, compared with 114.9 million in CT, MRI, PET and nuclear medicine systems combined. This positions the x-ray market well in comparison to larger modalities should healthcare providers seek to implement budget cuts.
Emerging markets, however, are going to be hit harder, especially as markets such as Brazil and Mexico continue to deal with the rising impact of COVID-19 with limited resources and no obvious plan to counter the pandemic. General radiography market growth in some emerging regions is therefore expected to be dampened throughout the forecast; emerging markets account for around 26.5% of the global market, with Latin America, Russia, and India expected to be most impacted.
Will a second peak affect the market?
A further unknown on the horizon for most healthcare providers and vendors is the possibility of a "second peak" of COVID-19 cases. How much of an impact would a second peak have on the market?
In our opinion, there would be only a limited impact for general radiography and fluoroscopy x-ray. System demand for mobile imaging has already been addressed through emergency tenders. Vendors are also prepared for the pandemic to roll on throughout 2020; GE Healthcare Chairman and CEO Larry Culp exemplified this sentiment in the company's latest earnings call.
"We're ramping production of critical medical equipment used to diagnose and treat COVID-19 patients, including respiratory, CT, monitoring solutions, x-ray, anaesthesia, and point of care ultrasound product lines," Culp said.
Markets are therefore only likely to be affected in the case of reverting to more stringent lockdowns, limiting access to hospital sites for installation of equipment, further delaying revenue. However, assuming imaging volumes will return to prepandemic levels in the interim, and reserves of critical care equipment will have been met, the impact of a second peak in most markets should be less pronounced than the first wave.
Where will change be most noticeable after COVID-19?
Radiography equipment can be found in acute hospitals, outpatient imaging centers, and urgent care clinics. The balance of where radiography is performed is perhaps the most likely to change. Outpatient imaging centers broadly experienced the steepest decline across all imaging modalities following the emergence of the SARS-CoV-2 virus. This is shown in Figure 2. We also would expect patients may modify their behavior to avoid exposing patients to imaging in hospitals. For this reason, outpatient x-ray imaging could become more common in the postpandemic future.
In the U.S., outpatient imaging centers typically operate on tight budgets; the recent loss of revenue from decreased demand could lead toward more interest in value-priced solutions and retrofit equipment to manage capital outlay. A general trend toward floor-mounted systems, which are priced more cost-effectively than ceiling-mounted systems, could also be accelerated. With increased patient demand, our upside scenario would also see substantial investment in replacing aging radiography equipment in the outpatient setting for systems supporting higher patient throughput.
Conclusion
Although market predictions currently come with a higher than usual sense of uncertainty in the current climate, the midterm outlook for general radiography and fluoroscopy market is still promising. General radiography equipment is one of the most-used imaging modalities worldwide; with easing of pandemic measures expected over the next few months, we are interpreting a broad market recovery in the next two years.
However, with some leading emerging growth markets struggling to contain the pandemic and the threat of a "second wave" of COVID-19 a possibility, several risks to market recovery still exist.
Imogen Fitt is a market analyst at Signify Research, a health tech, market-intelligence firm based in Cranfield, U.K. Competing interests: None declared.
The comments and observations expressed herein do not necessarily reflect the opinions of AuntMinnie.com or AuntMinnieEurope.com, nor should they be construed as an endorsement or admonishment of any particular vendor, analyst, industry consultant, or consulting group.
